AffiliationDepartment of Medicine, Respiratory Research Royal College of Surgeons in, Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Gene Expression Regulation
Secretory Leukocyte Peptidase Inhibitor/*metabolism
MetadataShow full item record
CitationBiochem Soc Trans. 2011 Oct;39(5):1421-6.
JournalBiochemical Society transactions
AbstractDuring the course of certain inflammatory lung diseases, SLPI (secretory leucoprotease inhibitor) plays a number of important roles. As a serine antiprotease it functions to protect the airways from proteolytic damage due to neutrophil and other immune cell-derived serine proteases. With respect to infection it has known antimicrobial and anti-viral properties that are likely to contribute to host defence. Another of its properties is the ability to control inflammation within the lung where it can interfere with the transcriptional induction of pro-inflammatory gene expression induced by NF-kappaB (nuclear factor kappaB). Thus, factors that regulate the expression of SLPI in the airways can impact on disease severity and outcome. Gender represents once such idiosyncratic factor. In females with CF (cystic fibrosis), it is now thought that circulating oestrogen contributes, in part, to the observed gender gap whereby females have worse disease and poorer prognosis than males. Conversely, in asthma, sufferers who are females have more frequent exacerbations at times of low-circulating oestrogen. In the present paper, we discuss how SLPI participates in these events and speculate on whether regulatory mechanisms such as post-transcriptional modulation by miRNAs (microRNAs) are important in the control of SLPI expression in inflammatory lung disease.
- The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses.
- Authors: Weldon S, McGarry N, Taggart CC, McElvaney NG
- Issue date: 2007 Apr
- Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
- Authors: Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC
- Issue date: 2009 Dec 15
- Secretory leukocyte peptidase inhibitor and lung cancer.
- Authors: Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T
- Issue date: 2008 May
- Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester.
- Authors: Maruyama M, Hay JG, Yoshimura K, Chu CS, Crystal RG
- Issue date: 1994 Jul
- SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.
- Authors: Zani ML, Tanga A, Saidi A, Serrano H, Dallet-Choisy S, Baranger K, Moreau T
- Issue date: 2011 Oct